Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Qilu In-Licenses siRNA Targeting PCSK9 from Ribo in $100 Million Agreement

publication date: Dec 28, 2023

Jinan Qilu Pharma in-licensed greater China rights to PCSK9-targeting antisense oligonucleotide from Suzhou Ribo Life Science in a deal worth $100 million in upfront and milestone payments, plus royalties. Qilu will have development, production, and commercialization rights to RED7022, a small interfering RNA drug aimed at treating hyperlipidemia. The candidate inhibits the expression of PCSK9 protein, reducing lysosomal degradation of low-density lipoprotein receptors. It is currently in a China Phase I trial. Qilu offers active pharmaceutical ingredients and finished drugs, but also develops innovative drugs. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital